Sort By
  • Newest

  • Newest

  • Oldest

  • Author Name

  • Author Name

  • Contributor

  • James Dunn

The race for a COVID-19 vaccine – are we there yet?

Executive summary Societies and governments around the world are looking at a COVID-19 vaccine as the panacea that will enable the world to recover, reconnect and regain our way of life. Since the genetic code for COVID-19 was unlocked, researchers have set out in an unprecedented and coordinated effort to make a vaccine available on…

Contributor | 9th Nov 2020 | More
Thinking ahead – ASX MedTech leaders

Here’s the fourth instalment of our series on the fascinating ASX cohort of medical device developers. ImpediMed (IPD, 8.1 cents)Market capitalisation: $83.8 millionThree-year total return: -52.7% a yearAnalysts’ consensus target price: 14 cents (Thomson Reuters) You would not know it from the share price performance over the last few years, but Brisbane-based ImpediMed has put…

James Dunn | 12th Oct 2020 | More